Avalon GloboCare Corp., along with its affiliated entities, possesses and manages commercial real estate assets across both the United States and the People's Republic of China. Beyond its real estate ventures, the company provides a suite of medical consulting offerings. These encompass conducting research studies, delivering executive education, issuing daily online executive briefings, and furnishing customized expert advisory services. Furthermore, it offers specialized consulting and management expertise in fields such as immunotherapy and services for obtaining second opinions or referrals. A core part of its biopharmaceutical pipeline includes two prominent CAR-T cell therapy candidates. AVA-001, an anti-CD19 therapy, has successfully concluded its initial human clinical trial for treating relapsed/refractory B-cell lymphoblastic leukemia. Meanwhile, AVA-011 has finished its preclinical laboratory evaluations and is currently advancing through the IND-enabling process development phase, which aims to produce cGMP-grade AVA-011 CAR-T cells. The company is also engineering an RNA-based FASH-CARTM cell therapy platform. Furthermore, Avalon GloboCare is involved in creating avalon clinical-grade tissue-specific exosomes (ACTEX). It collaborates with the Massachusetts Institute of Technology (MIT) to identify therapeutic and diagnostic targets using QTY-code protein design technology. This collaboration specifically extends to employing the QTY code for the invention of a hemofiltration device designed to manage Cytokine Storm. In partnership with Arbele Limited, it engages in the co-development of advanced, transposon-based, multi-target CAR-T, CAR-NK, and various other immune effector cell therapeutic approaches. The company has also forged a strategic alliance with the University of Natural Resources and Life Sciences in Vienna, Austria, focused on devising an S-layer vaccine for intranasal or oral administration, targeting SARS-CoV-2 and the coronavirus responsible for COVID-19. Additionally, it develops Avalon Cell and Avalon Rehab programs and actively champions standardization initiatives within the exosome industry. Its corporate headquarters are situated in Freehold, New Jersey.